Rapid Subcutaneous IgG Replacement Therapy is Effective and Safe in Children and Adults with Primary Immunodeficiencies—A Prospective, Multi-National Study

Rosen FS, Eibl M, Roifman C, Fischer A, Volanakis J, Aiuti F, Notarangelo L, Kishimoto T, Resnick IB, Hammarström L, Seger R, Chapel H, Cooper MD, Geha RS, Good RA, Waldmann TA, Wedgwood RJP: Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. Clin Exp Immunol 118(Suppl. 1):1–28, 1999

Chapel HM for the Consensus Panel for the diagnosis and management of primary antibody deficiencies: Consensus on diagnosis and management of primary antibody deficiencies. BMJ 308:581–585, 1994

Gardulf A, Hammarström L, Smith CIE: Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 338:162–166, 1991

Gardulf A, Andersen V, Björkander J, Ericson D, Frøland SS, Gustafson R, Hammarström L, Jacobsen MB, Jonsson E, Möller G, Nyström T, Soeberg B, Smith CIE: Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: Safety and costs. Lancet 345:365–369, 1995

Thomas MJ, Brennan VM, Chapel HM: Rapid subcutaneous immunoglobulin infusions in children. Lancet 342:1432–1433, 1993

Abrahamsen TG, Sandersen H, Bustnes A: Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics 98:1127–1131, 1996

Gaspar J, Gerritsen B, Jones A: Immunoglobulin replacement therapy by rapid subcutaneous infusions. Arch Dis Child 79:48–51, 1998

Chapel HM, Spickett GP, Ericson D, Engl W, Eibl M, Björkander J: The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 20:94–100, 2000

Stiehm ER, Casillas AM, Finkelstein JZ, Gallagher K, Groncy PM, Kobayashi RH, Oleske JM, Roberts RL, Sandberg ET, Wakim ME: Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiencies: Use of an old method with a new product. J Allergy Clin Immunol 101:848–849, 1998

Radinsky S, Bonagura VR: Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin. J Allergy Clin Immunol 112:630–633, 2003

Duff KA, Roy S, Poll J, Berger M: IgG replacement by the subcutaneous route using preparations licensed in the USA for administration by other routes. J Allergy Clin Immunol 113:S43, 2003

Berger M: Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 112:1–7, 2004

Gustafson R, Gardulf A, Granert C, Hansen S, Hammarström L: Prophylactic therapy for selective IgA deficiency. Lancet 350:865, 1997

Berger M, Duff K, Poll J, Roy S: IgG replacement by the subcutaneous route using preparations licensed in the US for administration by other routes. In Intravenous immunoglobulins in the third millennium. Proceedings of the 5th International Symposium on IVIG, MC Dalakas, PJ Späth (eds). New York, USA, The Parthenon Publishing Group, 2004, pp 77–80

Gardulf A, Björvell H, Andersen V, Björkander J, Ericson D, Frøland S, Gustafson R, Hammarström L, Nyström T, Søeberg B, Smith CIE: Lifelong treatment with gammaglobulin to patients with primary antibody deficiencies: The patients' experiences of subcutaneous self-infusions and home therapy. J Adv Nurs 21:917–927, 1995

Gardulf A, Nicolay U, Asensio O, Bernatowska E, Böck A, Costa-Carvalho BT, Granert C, Haag S, Hernández D, Kiessling P, Kus J, Matamoros N, Niehues T, Schmidt S, Schulze I, Borte M: Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 114:936–941, 2004

Waniewski J, Gardulf A, Hammarström L: Bioavailability of gammaglobulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 14:90–97, 1994

Gustafson R, Hammarström L: Subcutaneous immunoglobulin replacement therapy. Ellipse 18:45–48, 2002

Högy B, Keinecke H-O, Borte M: Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German Statutory Health Insurance. Eur J Health Econom 50:24–29, 2005

Gardulf A: Rapid subcutaneous immunoglobulin replacement therapy in patients with primary antibody deficiency. Aspects of effectiveness, safety, home therapy, quality of life and costs. Stockholm, Sweden, Karolinska Institutet, 1994 (ISBN 91-628-1403-6)

Bristol DR: Clinical equivalence. J Biopharm Stat 9:561, 1999

Yu Z, Lennon VA: Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 340:227–228, 1999

Wells JV: Metabolism of immunoglobulins. In Basic and Clinical Immunology, 2nd edn. HH Fudenberg, DP Stites, JL Caldwell, JV Wells (eds). Los Altos, CA, USA, Lange Medical Publishing, 1999, pp 237–245

Ochs HD, Pinciaro PJ and the Octagam Study Group: Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 24:309–314, 2004

Adams PF, Hendershot GE, Marano MA: Current estimations from the National Health Interview Study, 1996. National Center for Health Statistics. Vital Health Stat 10(200): 1999

Borte M, Oertelt C, Högy B: Behandlung von patienten mit primären antikörpermangelsyndromen in Deutschland. (Treatment of patients with primary antibody deficiencies in Germany). Klein Pädiatr 217:276–280, 2005 (Abstract in English)

Gardulf A, Björvell H, Gustafson R, Hammarström L, Smith CIE: Safety of rapid subcutaneous gammaglobulin infusions in patients with primary antibody deficiency. Immunodeficiency 4:81–84, 1993

Björkander J, Wadsworth C, Hansson L-Å: 1040 prophylactic infusions with an unmodified intravenous immunoglobulin product causing few side-effects in patients with antibody deficiency syndromes. Infection 13:102–110, 1985

Thampakkul S, Ballow M: Replacement intravenous immune serum globulin therapy in patients with antibody deficiency. Immunol Allergy Clin North Am 21:165–184, 2001

Hansen S, Gustafson R, Smith CIE, Gardulf A: Subcutaneous IgG infusions in patients with primary antibody deficiencies: Decreased time of delivery with maintained safety. Clin Immunol 104:237–241, 2002

Note for guidance on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) (CPMP/BPWG/388/95 rev. 1): The European Agency for the Evaluation of Medical Products; Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products, 1999

Note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use (CPMP/BPWG/283/00): The European Agency for the Evaluation of Medical Products; Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products, 2002 (operation date 2003)